Sensorion to Participate in JP Morgan Healthcare Conference in January

Presentation by CEO Nawal Ouzren

According to the press release, Nawal Ouzren, CEO of Sensorion, will deliver a presentation on January 15, 2026, at 8:15 AM Pacific Time, which is 5:15 PM Paris Time. A question-and-answer session will follow her presentation. The French company, specializing in the development of innovative therapies for hearing disorders, will use this platform to showcase its advancements. The JP Morgan Healthcare Conference is a major event in the health and biotechnology sector.

Development of Gene Therapy Programs

The company reports that Sensorion is currently developing two gene therapy programs aimed at correcting monogenic hereditary forms of deafness, in a strategic collaboration with the Pasteur Institute. The SENS-501 program, also known as OTOF-GT, is in a phase 1/2 clinical trial targeting deafness caused by mutations in the gene encoding otoferlin. The second program, GJB2-GT, addresses hearing loss related to mutations in the GJB2 gene, targeting significant segments of hearing loss in adults and children. The company is also working on identifying biomarkers to improve the diagnosis of these conditions.

Portfolio Includes SENS-401, a Clinical Small Molecule

Sensorion's portfolio also includes SENS-401, a clinical small molecule also known as Arazasetron, the company indicates. This drug candidate has advanced through three phase 2 proof-of-concept clinical studies. The first addresses cisplatin-induced ototoxicity to preserve residual hearing, with recruitment completed and follow-up ongoing. The second study, conducted with partner Cochlear Limited, focuses on the preservation of residual hearing in patients scheduled for cochlear implantation and concluded in 2024. The third phase 2 study concerning sudden sensorineural hearing loss concluded in 2022.